TY - JOUR
T1 - Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study)
T2 - Report 1
AU - Fan, Wenying
AU - Nittala, Muneeswar Gupta
AU - Velaga, Swetha B.
AU - Hirano, Takao
AU - Wykoff, Charles C.
AU - Ip, Michael
AU - Lampen, Shaun I.R.
AU - van Hemert, Jano
AU - Fleming, Alan
AU - Verhoek, Michael
AU - Sadda, Srini Vas R.
N1 - Funding Information:
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest and the following were reported. C.W.C is a consultant for Alimera Sciences (Alpharetta, Georgia), Allergan (Dublin, Ireland), Alnylam (Cambridge, Massachusetts), Bayer (Leverkusen, Germany), Clearside Biomedical (Alpharetta, Georgia), Dutch Ophthalmic Research Center (Exeter, New Hampshire), Genentech (South San Francisco, California), Navigant (Chicago, Illinois), ONL Therapeutics (Ann Arbor, Michigan), Regeneron Pharmaceuticals (Tarrytown, New York), Thrombogenics (Leuven, Belgium), and Valeant (Laval, Canada); is on the speaker's bureaus of Allergan (Dublin, Ireland), Apellis Pharmaceutical (Crestwood, Kentucky), Clearside Biomedical (Alpharetta, Georgia), DRCR Network (Tampa, Florida), Genentech (South San Francisco, California), Iconic Therapeutics (San Francisco, California), Ophthotech (New York, New York), Regeneron Pharmaceuticals (Tarrytown, New York), Thrombogenics (Leuven, Belgium), and Tyrogenex (Rockville, Maryland); and receives lecture fees from Allergan (Dublin, Ireland) and Regeneron Pharmaceuticals (Tarrytown, New York). M.I. is a consultant for Thrombogenics (Leuven, Belgium), Omeros (Seattle, Washington): Code C, Boehringer Ingelheim (Ingelheim am Rhein, Germany), and Genentech (South San Francisco, California). SV.R.S. receives grant fees from Genentech (South San Francisco, California), Allergan (Dublin, Ireland), Optos (Dunfermline, United Kingdom), and Carl Zeiss Meditec (Dublin, California); and is a consultant for Genentech (South San Francisco, California), Allergan (Dublin, Ireland), Optos (Dunfermline, United Kingdom), Novartis (Basel, Switzerland), Thrombogenics (Leuven, Belgium), and Iconic (San Francisco, California). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors attest that they meet the current ICMJE requirements to qualify as authors.
Publisher Copyright:
© 2019 Elsevier Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/10
Y1 - 2019/10
N2 - Purpose: To explore the distribution of nonperfusion area (NPA) on ultrawide-field fluorescein angiography (UWF FA) in proliferative diabetic retinopathy (PDR) and its relationship with the presence of neovascularization of the optic disc (NVD) and distribution of neovascularization elsewhere (NVE). Design: Prospective, observational case series. Methods: Baseline Optos 200Tx UWF FA images of 38 eyes with treatment-naïve early-stage PDR from the RECOVERY (NCT02863354) study were stereographically projected at the Doheny Image Reading Center. Two independent/masked certified graders manually delineated the NPA and the total visible retinal area (TRA). NPA and TRA were then computed in square millimeters using the manufacturer software. Ischemic index (ISI) was calculated by dividing NPA by TRA. NPA and ISI were correlated with the presence and distribution of neovascularization in the corresponding zones. Results: Eyes with NVD appeared to have more severe global NPA than those without (P =.026). Although the ISI appeared to increase with increasing distance from the foveal center (P <.001), NVE was more likely to be located in the posterior pole than the midperiphery or far-periphery (P <.001). Presence of NVE in the posterior polar retina appeared to demonstrate more severe ischemia in the posterior pole and midperiphery than those without (P <.05), but interestingly, was not correlated with the severity of overall global ischemia or of ischemia in the far-periphery alone (P >.05). Conclusions: Whereas the presence of NVD was associated with the severity of global ischemia, the distribution of NVE did not appear to be influenced by the distribution of ischemia.
AB - Purpose: To explore the distribution of nonperfusion area (NPA) on ultrawide-field fluorescein angiography (UWF FA) in proliferative diabetic retinopathy (PDR) and its relationship with the presence of neovascularization of the optic disc (NVD) and distribution of neovascularization elsewhere (NVE). Design: Prospective, observational case series. Methods: Baseline Optos 200Tx UWF FA images of 38 eyes with treatment-naïve early-stage PDR from the RECOVERY (NCT02863354) study were stereographically projected at the Doheny Image Reading Center. Two independent/masked certified graders manually delineated the NPA and the total visible retinal area (TRA). NPA and TRA were then computed in square millimeters using the manufacturer software. Ischemic index (ISI) was calculated by dividing NPA by TRA. NPA and ISI were correlated with the presence and distribution of neovascularization in the corresponding zones. Results: Eyes with NVD appeared to have more severe global NPA than those without (P =.026). Although the ISI appeared to increase with increasing distance from the foveal center (P <.001), NVE was more likely to be located in the posterior pole than the midperiphery or far-periphery (P <.001). Presence of NVE in the posterior polar retina appeared to demonstrate more severe ischemia in the posterior pole and midperiphery than those without (P <.05), but interestingly, was not correlated with the severity of overall global ischemia or of ischemia in the far-periphery alone (P >.05). Conclusions: Whereas the presence of NVD was associated with the severity of global ischemia, the distribution of NVE did not appear to be influenced by the distribution of ischemia.
UR - http://www.scopus.com/inward/record.url?scp=85068896079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068896079&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.04.023
DO - 10.1016/j.ajo.2019.04.023
M3 - Article
C2 - 31078541
AN - SCOPUS:85068896079
SN - 0002-9394
VL - 206
SP - 154
EP - 160
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -